Zhang Jia Jie Shi

Researchers are evaluating the safety and effectiveness of TQB2930, a HER2 bispecific antibody drug, combined with a choice of chemotherapy drugs, compared to trastuzumab combined with chemotherapy in people with HER2-positive advanced breast cancer. The study focuses on participants who have already received at least two prior anti-HER2 treatments for their advanced cancer. This is a Phase III clinical trial designed to compare these two treatment approaches. Participants will receive either TQB2930 plus chemotherapy or trastuzumab plus chemotherapy. The chemotherapy options include capecitabine tablets, gemcitabine hydrochloride injection, vinorelbine tartrate injection, and eribulin mesylate injection. Treatments are given according to the investigator's choice alongside the study drugs. The study is randomized, open-label, and conducted at multiple centers. During the study, participants will be monitored for progression-free survival, which means the length of time they live without the cancer worsening, up to about one year. Researchers will assess treatment response through measurable lesions and monitor safety and side effects. Various tests and evaluations will be performed throughout the study to track health status and treatment effects. The study includes follow-up to evaluate the overall outcome and safety of the treatments.